Onconetix (ONCO) Competitors

Onconetix logo
$2.89 -0.27 (-8.54%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.88 -0.01 (-0.35%)
As of 11/20/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ONCO vs. MTVA, ALVR, GTBP, XCUR, and IMRN

Should you buy Onconetix stock or one of its competitors? Onconetix's main competitors and comparable companies include MetaVia (MTVA), AlloVir (ALVR), GT Biopharma (GTBP), Exicure (XCUR), and Immuron (IMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Onconetix compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

MetaVia presently has a consensus price target of $20.00, suggesting a potential upside of 1,880.20%. Given MetaVia's stronger consensus rating and higher possible upside, research analysts plainly believe MetaVia is more favorable than Onconetix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MetaVia
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

MetaVia has a net margin of 0.00% compared to Onconetix's net margin of -7,408.07%. Onconetix's return on equity of -44.73% beat MetaVia's return on equity.

Company Net Margins Return on Equity Return on Assets
MetaViaN/A -265.53% -129.86%
Onconetix -7,408.07%-44.73%-14.77%

In the previous week, MetaVia had 12 more articles in the media than Onconetix. MarketBeat recorded 15 mentions for MetaVia and 3 mentions for Onconetix. Onconetix's average media sentiment score of 1.00 beat MetaVia's score of 0.91 indicating that Onconetix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MetaVia
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Onconetix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

1.4% of MetaVia shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 0.6% of MetaVia shares are held by insiders. Comparatively, 0.3% of Onconetix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MetaVia has higher earnings, but lower revenue than Onconetix. MetaVia is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetaViaN/AN/A-$12.97M-$2.38N/A
Onconetix$810K2.11-$14.03M$5.53 thousand0.00

MetaVia has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market.

Summary

Onconetix beats MetaVia on 8 of the 15 factors compared between the two stocks.

How does Onconetix compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

AlloVir has a net margin of 0.00% compared to Onconetix's net margin of -7,408.07%. Onconetix's return on equity of -44.73% beat AlloVir's return on equity.

Company Net Margins Return on Equity Return on Assets
AlloVirN/A -71.03% -61.27%
Onconetix -7,408.07%-44.73%-14.77%

In the previous week, Onconetix had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Onconetix and 0 mentions for AlloVir. Onconetix's average media sentiment score of 1.00 beat AlloVir's score of 0.00 indicating that Onconetix is being referred to more favorably in the news media.

Company Overall Sentiment
AlloVir Neutral
Onconetix Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AlloVir
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.62, meaning that its stock price is 162% more volatile than the broader market.

Onconetix has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/A-$190.42M-$20.23N/A
Onconetix$810K2.11-$14.03M$5.53 thousand0.00

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Onconetix beats AlloVir on 10 of the 13 factors compared between the two stocks.

How does Onconetix compare to GT Biopharma?

Onconetix (NASDAQ:ONCO) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 1.1% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GT Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Onconetix had 1 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for Onconetix and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.50 beat Onconetix's score of 1.00 indicating that GT Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Onconetix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GT Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Onconetix has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Onconetix has higher revenue and earnings than GT Biopharma. GT Biopharma is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Onconetix$810K2.11-$14.03M$5.53 thousand0.00
GT BiopharmaN/AN/A-$28.35M-$128.73N/A

GT Biopharma has a net margin of 0.00% compared to Onconetix's net margin of -7,408.07%. Onconetix's return on equity of -44.73% beat GT Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Onconetix-7,408.07% -44.73% -14.77%
GT Biopharma N/A -178.57%-128.19%

Summary

Onconetix beats GT Biopharma on 8 of the 11 factors compared between the two stocks.

How does Onconetix compare to Exicure?

Exicure (NASDAQ:XCUR) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Exicure had 3 more articles in the media than Onconetix. MarketBeat recorded 6 mentions for Exicure and 3 mentions for Onconetix. Onconetix's average media sentiment score of 1.00 beat Exicure's score of 0.83 indicating that Onconetix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exicure
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Onconetix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Exicure has a beta of 3.83, meaning that its share price is 283% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.62, meaning that its share price is 162% more volatile than the broader market.

Exicure has a net margin of 0.00% compared to Onconetix's net margin of -7,408.07%. Onconetix's return on equity of -44.73% beat Exicure's return on equity.

Company Net Margins Return on Equity Return on Assets
ExicureN/A -237.91% -61.98%
Onconetix -7,408.07%-44.73%-14.77%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exicure
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Exicure has higher earnings, but lower revenue than Onconetix. Exicure is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ExicureN/AN/A-$4.95M-$0.83N/A
Onconetix$810K2.11-$14.03M$5.53 thousand0.00

42.8% of Exicure shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Exicure and Onconetix tied by winning 6 of the 12 factors compared between the two stocks.

How does Onconetix compare to Immuron?

Onconetix (NASDAQ:ONCO) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Immuron
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Onconetix had 2 more articles in the media than Immuron. MarketBeat recorded 3 mentions for Onconetix and 1 mentions for Immuron. Onconetix's average media sentiment score of 1.00 beat Immuron's score of 0.00 indicating that Onconetix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Onconetix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immuron has a net margin of 0.00% compared to Onconetix's net margin of -7,408.07%. Immuron's return on equity of 0.00% beat Onconetix's return on equity.

Company Net Margins Return on Equity Return on Assets
Onconetix-7,408.07% -44.73% -14.77%
Immuron N/A N/A N/A

Onconetix has a beta of 2.62, meaning that its share price is 162% more volatile than the broader market. Comparatively, Immuron has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Immuron has higher revenue and earnings than Onconetix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Onconetix$810K2.11-$14.03M$5.53 thousand0.00
Immuron$5.47M1.33-$2.50MN/AN/A

Summary

Immuron beats Onconetix on 6 of the 11 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCO vs. The Competition

MetricOnconetixBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.70M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.62%
P/E Ratio0.0023.0732.5628.68
Price / Sales2.1114.927.725.17
Price / CashN/A21.9220.2520.77
Price / Book-0.104.124.343.51
Net Income-$14.03M-$24.08M$3.51B$394.12M
7 Day Performance-9.97%-9.85%-8.07%-8.97%
1 Month Performance-28.96%-12.77%-10.29%-11.61%
1 Year Performance-99.74%-7.99%-4.70%-11.21%

Onconetix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCO
Onconetix
0.756 of 5 stars
$2.89
-8.5%
N/A-99.7%$1.70M$810K0.002
MTVA
MetaVia
2.8759 of 5 stars
$1.08
-14.0%
$20.00
+1,760.5%
-86.8%$7.25MN/AN/A8
ALVR
AlloVir
N/A$1.43
-2.1%
N/A-81.4%$7.21MN/AN/A110
GTBP
GT Biopharma
0.9462 of 5 stars
$3.44
+8.2%
N/A-83.9%$7.09MN/AN/A1
XCUR
Exicure
0.63 of 5 stars
$1.07
-1.4%
N/A-78.4%$6.98M$500KN/A50

Related Companies and Tools


This page (NASDAQ:ONCO) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners